GlassScriptPhysician profile
Richard Gardner Mitchell
NPI 1457434920
$5,516.00
in general payments reported to CMS, 2019-2025
34 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $256 · 2021: $599 · 2022: $1,429 · 2023: $661 · 2024: $713 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811 · Education: $35.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.82 |
| Education | $35.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.53 | 2019-2025 | |
| Janssen Biotech, INC. | $966.02 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.89 | 2019-2025 | Xifaxan, Trulance |
| Erbe USA INC | $521.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.32 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $277.80 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $255.05 | 2022-2025 | |
| Braintree Laboratories, INC. | $220.33 | 2019-2022 | |
| Pfizer INC. | $166.14 | 2020-2025 | |
| Lilly USA, LLC | $119.07 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $93.08 | 2021-2023 | Injectafer |
| Gilead Sciences, INC. | $81.52 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $56.70 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $52.23 | 2025 | Iqirvo |
| Ardelyx, INC. | $49.08 | 2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $44.68 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $40.49 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $38.63 | 2022-2024 | Rebyota |
| Celltrion USA INC. | $35.12 | 2024 | Zymfentra |
| Sandoz INC. | $34.91 | 2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $34.57 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $34.24 | 2019-2024 | |
| Vivus LLC | $32.35 | 2021 | |
| Merck Sharp & Dohme LLC | $27.90 | 2023 | Dificid |
| Olympus America INC. | $26.16 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $21.45 | 2024 | Monoferric |
| Aimmune Therapeutics, INC. | $21.15 | 2025 | Zenpep |
| Shire North American Group INC | $18.51 | 2019 | |
| Novo Nordisk INC | $17.66 | 2025 | Wegovy |
| Concordia Pharmaceuticals INC. | $14.74 | 2019 | |
| Organon LLC | $14.26 | 2021-2024 | Renflexis, Hadlima |
| Endo Pharmaceuticals INC. | $12.34 | 2019 | |
| Allergan, INC. | $11.94 | 2020 | |
| Romark Laboratories, Lc | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.